Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

721 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Nebot-Bral L, Hollebecque A, Yurchenko AA, de Forceville L, Danjou M, Jouniaux JM, Rosa RCA, Pouvelle C, Aoufouchi S, Vuagnat P, Smolenschi C, Colomba E, Leary A, Marabelle A, Scoazec JY, Cassard L, Nikolaev S, Chaput N, Kannouche P. Nebot-Bral L, et al. Among authors: scoazec jy. J Immunother Cancer. 2022 Jul;10(7):e005059. doi: 10.1136/jitc-2022-005059. J Immunother Cancer. 2022. PMID: 35896284 Free PMC article.
Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
Martin-Romano P, Adam J, Scoazec JY, Gouy S, Levy A, Baldini C, Champiat S, Soria JC, Massard C, Marabelle A, Deutsch E, Hollebecque A. Martin-Romano P, et al. Among authors: scoazec jy. Front Immunol. 2021 Nov 4;12:745146. doi: 10.3389/fimmu.2021.745146. eCollection 2021. Front Immunol. 2021. PMID: 34804027 Free PMC article.
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.
Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N. Coutzac C, et al. Among authors: scoazec jy. J Crohns Colitis. 2017 Oct 1;11(10):1238-1246. doi: 10.1093/ecco-jcc/jjx081. J Crohns Colitis. 2017. PMID: 28967957
Ovarian Cancer: A Heterogeneous Disease.
Kossaï M, Leary A, Scoazec JY, Genestie C. Kossaï M, et al. Among authors: scoazec jy. Pathobiology. 2018;85(1-2):41-49. doi: 10.1159/000479006. Epub 2017 Oct 12. Pathobiology. 2018. PMID: 29020678
Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers.
Lambert T, Pobel C, Colmet-Daage L, Bigorgne A, RaubyY B, Aladro NS, Ter-MinassianN L, Kerisit M, Marabelle A, Besse B, Hollebecque A, Champiat S, Massard C, Morel D, Verlingue L, Scoazec JY. Lambert T, et al. Among authors: scoazec jy. Cancer Treat Res Commun. 2022;32:100611. doi: 10.1016/j.ctarc.2022.100611. Epub 2022 Jul 19. Cancer Treat Res Commun. 2022. PMID: 35905672 Free article.
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C. Verlingue L, et al. Among authors: scoazec jy. Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3. Eur J Cancer. 2018. PMID: 29413684
Immunodynamics of explanted human tumors for immuno-oncology.
Dubuisson A, Fahrner JE, Goubet AG, Terrisse S, Voisin N, Bayard C, Lofek S, Drubay D, Bredel D, Mouraud S, Susini S, Cogdill A, Rebuffet L, Ballot E, Jacquelot N, Thomas de Montpreville V, Casiraghi O, Radulescu C, Ferlicot S, Figueroa DJ, Yadavilli S, Waight JD, Ballas M, Hoos A, Condamine T, Parier B, Gaudillat C, Routy B, Ghiringhelli F, Derosa L, Breuskin I, Rouanne M, André F, Lebacle C, Baumert H, Wislez M, Fadel E, Cremer I, Albiges L, Geoerger B, Scoazec JY, Loriot Y, Kroemer G, Marabelle A, Bonvalet M, Zitvogel L. Dubuisson A, et al. Among authors: scoazec jy. EMBO Mol Med. 2021 Jan 11;13(1):e12850. doi: 10.15252/emmm.202012850. Epub 2020 Dec 29. EMBO Mol Med. 2021. PMID: 33372722 Free PMC article.
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C. Sun R, et al. Among authors: scoazec jy. Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14. Lancet Oncol. 2018. PMID: 30120041
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.
Pasqualini C, Rubino J, Brard C, Cassard L, André N, Rondof W, Scoazec JY, Marchais A, Nebchi S, Boselli L, Grivel J, Aerts I, Thebaud E, Paoletti X, Minard-Colin V, Vassal G, Geoerger B. Pasqualini C, et al. Among authors: scoazec jy. Eur J Cancer. 2021 Jun;150:53-62. doi: 10.1016/j.ejca.2021.03.032. Epub 2021 Apr 20. Eur J Cancer. 2021. PMID: 33892407 Clinical Trial.
721 results